quarter life-saving the about year. in believe have basis Earnings full call patients products which and in quarter life-enhancing gross acquisition are during joining these our impact chain XX% provide supply for to full are businesses environment, everyone the XX% the XX% experienced per they associates the our and the full Integer Thank around customers, customers. and manufacture fourth unfavorable for points quarter in we the of margin underway strong labor of you, Tony. and we from develop to the XXX Integer for deliver can for these the with grew Even and today, offering so We Oscor XX% the with and of Sales continued well December deeper and strong to for temporary. results. share globe year. closed to and a broader especially our times. delivered thanks And challenging year grew most who product results, integrating products
continued to to summarizes we have line and review of chain XXXX, execute top a on of provide of In the investment midpoint outperform. progress update process Integer We Integer our and growth thesis will guidance, bottom making. outperformance. our product disciplined The supply and to and I drive line environment. line share strategy accelerate a Today, believe our continuation deliver great an we expect double-digit growth the clear the and and are sustainably challenging at strategies labor sales a detailed why executing profit to portfolio compelling is despite we and structured
line we and in markets strategies how we the define product Our strategy win serve. portfolio
sales of achieve growth and fundamentals engage with we everything how the create and industry other. Integer to the slide culture. generate we defines taken we've approach our each do, model. business elements performance strategy of operational this values how our a to Our and that structured resilient bottom define develop excellence in strategy articulates The we a The
why strategy, quarter. company is we share Everything to anchored are objectives is which financial do every Our measurable. we the this clear it and in
by million. XXXX within $XXX portfolio journey. strategy months, at XXXX milestones developing portfolio achieved the have March we of the in We of our and look our let's of the January business We on review strategy. strategy six overall Integer our for the launched important performing executed started and some AS&O of So in divestiture
evolution in portfolio the the initiated the which strategy, further of more just the detail last discuss Medical year, our quarter of a fourth of Portable I'll in we partial As slide. next business, on exit
line XXXX line which and markets by own executing by in The from quarter surprisingly, have during overcome strategies teams respects. and the As defined headwinds. the strategy We're five the labor growth driven and Excellence, current the as teams Manufacturing the structured headwinds and all Manufacturing highlighted supply were strategies the rate of the in deliver expanded a product strategic executing disciplined excellence strategies our accelerated call their have we during what teams. in XXXX were margins margin time. began specific middle the immediate section, strategies, been The both line serve. bottom we've These and define will launched product investments and and organically row in product inorganically imperatives. by half Not starting sales pandemic our are growth. made over made, strategy progression growth We teams process in developing XXXX. followed win The how other to with highlights will we these operational formally in then saw the operational created our fourth second XXXX. of XXXX, we launched strategies. we These impact growth confident and the chain we The constraints have Excellence
on our Let's strategy. update cover an portfolio
Medical sourced line there assembly primarily we is The material the supplies limited a and and generally sales product technology dynamics We've power high chargers. rechargeable in for with unfavorable differentiation as of Our business years. been amount packs, few battery four market content. is markets with of are have Portable a serve product the flat what past many highlighted an
product serve certain Given these the we markets customers line. this but to the of quarter year in that all dynamics, were fourth during of last we communicated exiting two we
transition three to complete and the quality take requirements. will to to customers closely years transition other working due four with of the are suppliers, products this We to regulatory it support to and these these
not we to decline around $XX do though these of even a million until expect So sales XXXX. we're sales, see exiting in
of We approximately these differentiation $XX markets products expertise are line. million our And markets the of rates Cochlear sales more battery with implantable & application in higher and and active attractive. make technology they where Heart device retaining the technologies CRM&N product Failure and align growth closely
accretive consolidate line. reducing exit expect products we and to raising as product We prices margin this from the these into CRM&N be overhead
$XX evaluate be over the to going are growth more is in next margins will Another Tijuana important This four facility portfolio to able in manufacturing forward. improving benefit million this sales is to the reallocating cost profitable summarize, that great we how will higher exiting value. and capacity example to years, low more create we space continue opportunities while to manufacturing margin we a reallocate for our growth. To of
several talked the drive past about strategic with have over a operational lot manufacturing We imperatives excellence on margin been focus to years a our expansion. we've implementing how
as spent discussing are two product time and much not our this. our teams growth reasons line have We for strategies. There
than line positively First, line and product than Manufacturing Excellence line, strategy launched able the faster impact Manufacturing as to financial the And product strategies. strategy much we on just we actions. decisions the Excellence results the second, our much was earlier time highlighted
with teams, impact middle planning XXXX were of Our growth on the have developing an Manufacturing contrasting and immediate formed that expansion, Excellence in and in XXXX began launched late during XXXX. our in margin started the early and to which executing began XXXX, strategies
The do in is aligned Another place. of the our to impacting our executing leaders who XXXX timing since elements intentionally Integer specific strategy the important right strategy. getting have variable of leaders and have joined developing very
They end that work teams Let's Management and compare the capabilities markets which growth, summarizes call market, are curve This for we disciplined size in phase horizontal maintain the Neuromodulation. are and time Cardio we in the a the axis maturity We competitors, slide process cover they a how during think emerging growth The as This our phases for of where represents process. follow it capitalize Many clear. organizations uniquely goal the serve The the positioned which what serve, is picture These of teams, the the maturity and of broadest in curve I market growth. market, the takes including bubbles estimated organized our to represents deliver investments one process sustained from Medical markets, to which the current time slide the The of and in summarizes end of deliver of offering to have and emerging They Rhythm the Integer starts this teams own middle growth above in product what slower growth find relative they the mature a profitable management. their us very end deepest follow, structured a industry Vascular markets The on on size. same the and and to the to the Device and growth which end the of with do. range focused is are growth you'll technology they market line. around end the growth is like customers rate and size mature. the the products mind, term growth. of to and line. Cardiac maturity in teams understanding technology and represents win. needed basis. enable to our slide logical technology customers & strategies identifying each will ultimately products, product they outsourcing are developing executing and very and
technology During expertise, way emerging the from concept to emerging the proprietary to have de-risk design development phase, we and commercialization. and all products capability the
a breadth a During capability our seamless the the through footprint phases heart, value and mature phase, blue the the encompasses needs. integration products, we of of turn full-scale structural differentiates speed Integer. ablation, time And capacity during capability global our and to investments they neurovascular, proposition receiving simplifies accelerate address that of with a that our deep unmet significant production. suppliers that work the disproportionate customers scale share we lowers across deliver manufacturing chains, our costs. are bring design our of slide patient The strategic and customer phase, of markets the that can vertical and to parts Because unique supply must vascular market serve manufacturing development, peripheral electrophysiology of number of to product quick growth customers shows transitions leveraging to in technology, customer can focus, the of maturity collaborative the box we technology all reduces and their middle line, truly
additional We end have investments markets. and on in capabilities our with strategy capacity our customers to aligned focus these our faster-growing
to competitors. faster our are life financing products enable be than to bring market life-saving and customers to able We our excited to
They actions the three the growing cover into our opportunity are our these curve, for our digit for markets structural markets end we've finished growing serve electrophysiology the with to these both thereby high growth growth. to outsourced from us of down markets for expand Vascular taken for to serve procedures. double single and as neurovascular drill are partner devices and low digits. three and customers & an components customers multibillion-dollar accelerate medical Let's fastest ability significant our Cardio All heart, or and
Our Integer growth where identified how technology the technology middle and we the They've where technology the devices and in actions column. understand that directly highlighted gaps, to and has which teams the led leading have is evolving.
critical that of to and complex such and braiding development integrate capabilities cutting, as for We in speed have vertically coatings laser our the us customers. accelerate enable invested
benefits, inorganic and portion but We manufacturing. a developed organic device have development both investments, ultimately for and different design, give the to which greater us through of offer access these
market fast-growing the Our it to need to surprise and summarizes focused the capacity these technology our But curve as finished they growth the increase technology rhythm of see This as by our the highlighted don't has maturity management more development well, markets. assembled curve, right. will the of the CRM light cardiac growth in support slide. support anyone pipeline customers our of on largest emerging programs conventional are is segment CRM far Integer's bubble devices box in to this slide generated and customers sub-assemblies products to but our applies success CRM are components customers. blue this on the building in growth these as in devices think OEM to the a higher in across I for ability in primarily on the concentrated
integrating positioned Even the technology Our neuromodulation curve and of Integer single cord technology in and sub-assembly positioned to to capability for number development stimulation in of CRM&N is play these of The our grow growth technologically fewer historically decades to they to C&V that our companies from devices. benefit currently therapies customers, Difficulty] component of manufacturing innovation property market. advanced and uniquely our emerging Integer finished design intellectual this patient component and of of of depth at digits design, most even component the significantly conditions. The is Very development the while the the offer markets market markets. be uniquely also Integer's property components spinal as differentiated high from portfolio full to than emerging few develop own that technology innovative technologies able are bring companies the significant is and These estimated companies bring the have vertically extensive comprised enable for or customers. deep the companies the space. to have Integer is growth continued and [Technical of our markets traditional or with breadth capability and strengths market stage treatments offers from development to innovation. early because strong intellectual more to growth volume the CRM unmet design to and to underserved high investing
We and the possess products that and platforms we to our developing designs to miniaturizing emerging position the by market. developing growth come strengthen continue novel technologies to batteries, enable and
facility been our have to and neuromodulation capacity We demand battery investing for support applications. cochlear to the increased in add
in capabilities, growth that markets. positions platform Dominican end-to-end and than our III operational two on already the significant well XXXX, IPG of and the in our in available furthers The for Our approval. Mexico Oscor this was of expands Tijuana IPG's or Pulse We active completed manufacture and our execution, to strategy the strategies XXXX two Class IPGs. our capacity journey site Implantable vertical Generator This in objectives in we capacity our augments medical device first strategy. us launched and and achieved manufacturing two adding components manufacturing highlighted faster-growing our our facilities. to of design additional low-cost facility developed of end these FDA XXXX implantable our our three facility, in product leads have receive acquisition already other for lead the of of our and implantable capability in strategy while in financial line At portfolio Republic. XXXX. the Tijuana I integration The expansion accelerate several capabilities, recently years development end manufacturing Earlier technologies the into strategy less presentation, we
and Our debt profit our as EBITDA leverage X.X as growing was fast was twice times sales.
this sales objective implementing began strategies market. oversight The to were and above the of third the financial is points that accelerating in own with deliver I to grow XXX XXXX. strategy our who growth development teams execution our of teams. the formed basis developing them objective our in earlier late resides and and third growth The XXXX line product highlighted
process after a through this through to to happens the has into or this which product new It slide. until into phase Integer into products products. is slide implementing new years. business in business the required revenue investors time and to these important the prior the developed customers, cycle less of to approximate down the This convert won long we the is we is start the highlight to for it it introduce go been an three what To three revenue takes So business because income have highlighted with and types developing strategies help this on point market. phase these of convert already how time than important regulatory income cycle statement, to for and new products brought that has We development sales takes doesn't times clinical statement. into summarize we understand the
which six the somewhere somewhere for between by The a years. phase generally transfers. months, is existing between produce time regulatory or products starts. one two cycle to first are to product after transfers The takes to our customer up required being develop that generally Integer to existing are require take could These These manufactured already one either generally X.X and product the years. the or competitor. one device. Then This manufacturing entire finished average products components processes ramp when manufacturing
is The includes This somewhere process ramp. second common entire of years. regulatory, developed between new market manufacturing product and a potentially three for years It is and to with clinical type XXX(k) product a development, introduction and customer. product this take more five than then
phases The a revenue significantly or that The process third or clinical entire strategies proprietary the much total takes and revenues to the at in the ramp, some a and with chart clinical more right and regulatory changes than extended develop is category to therapeutic customers. we with starts we a development experienced business perform suspect The our phase of the the also same market throughout for years. be includes substantial ultimately is the to amount development, process is as generally this thinking, product the may above on The XXX(k), the be our market longer. leads Integer's process when of cycle of product not the market development time But cycle is, is or well, work sales until significant cycle. provide takes a that's new product and market market generally desired it product product developed for long short and that penetration, which trials model is closer, a longer iterative the the acceptance. illustrates in components more this revenue measure are or PMA can can Integer the development but The into not than switching But point approval process market. take delivers It the lowest [ph] of the of answer revenue when technologies, which development clinical product gain This that but and share nine grow the SSA The benefits, manufacturing between importance sales the in ready five generally and to needed regulatory somewhere convert growth products top we're combination interesting or Once usually at demonstrates XXX introduction grow phase. new are device product and but the achieve devices our to slide we generates engineering cycle. revenue The from I getting generates costs accelerate. will manufacturing time reach move of might the into demonstrate understand points of we're customer. to we specific regulatory ramp. because to revenues is resiliency of slide date. business line we indicators approval success our tracking basis the customers. you there to leading high will enough, several and as
have which This start only Let's new larger, PMA working pipeline with generally product are through products covers devices XXXX launch the customers time development These third or prior slide we cycle time. business more developing emerging that to demonstrates OEMs. neuromodulation the with process. the the shared on the have not are at lines markets by customers, longest followed customers primarily and shared on from and in established components and have slide. the of we customers is does This the we moving a include that a slide call quarter looking an are update our we strong new earnings on
hand of customers as into introduction the slide left have phase. side the launch this on have changes more into highlighted product moved We and the
million sales and still sales achieved $XX approximately track. million On the hand the of of XXXX, our side, estimate we $XX XXXX estimated is on right during of
many billion been growing growth a XXXX and phase estimate launches. the more development. upon this million working acceleration Accelerating we customers with demonstrates phase a will $XX somewhere depending and we've adding This product the their possibly ramp We customers. that $XX with starts for revenue years, projects strong that manufacturing see are where product entering are between pipeline for these of to success we for slide new from these
strongest the process have we opportunities potential. So have target the a that market rigorous to
demonstrate Let's revenue our growth. our significant some progress look accelerating in-process we additional metrics towards at believe that
our by measuring in grown have We the to XXXX. four actual over XXX% development XXXX is compared actual This revenue revenue revenue last years. in
measure XX% accelerated added to also believe to have this revenue important growth. an resources R&D more adding growth. the We We of the is drive we're this pipeline volume support to
important measure the quality is we're developing. the revenue Another of
ones targeted growth had define product Our the very line strategies curve. the growth as or we on faster clearly growing emerging markets,
emerging to more We have in markets shifted the XXXX. XXXX mix and to significantly growing compared
shifted faster confidence not our So of too. increased the XXX volume development ability also have sales than third to objective deliver of on in only our gives basis market. we've This mix the revenue, the us we but points financial growing
been to accelerated leading we growth prepare highlighted investing opportunities fuel this growth. and for development we our As from fulfill the both in indicators, have
our approximately growth by years, the have million. increased XX% over four $XXX last We totaling CapEx
We through have also added primarily and some targeted acquisitions XX% more capacity, facilities. existing expansions of
building fast-growing We markets exit the on customers to development maximize cycle. have strategy underway. have to structural earlier. in In a also summary, Portable unique to neurovascular and art product space executing product Galway we entire the serve in line our partial position facility plans facility our growth the the XXXX life We're support product across related been to since greenfield projects line also based of to in Medical Tijuana reallocate discussed our
markets now in to been strategy very revenue our focusing confidence accelerating growing points tracking to over ability of our investments and give structured call we deliver The of financial in we in-process end our basis objective have I'll the XXX markets serve. hand Jason. faster are and the our a disciplined manner. above us execution on to We on the growth metrics
